埃拉特会议为基础和临床科学家讨论癫痫的新治疗提供了一个论坛,临床医生,以及来自监管机构和制药行业的代表,已有30年的历史。最初专注于药物治疗,Eilat会议现在还包括专门讨论治疗和监测设备的会议。第十六届埃拉特新型抗癫痫药物和器械会议(EILATXVI)在马德里举行,西班牙,2022年5月22日至25日,来自26个国家的157名代表参加了会议。和以前的埃拉特会议一样,EILATXVI的核心包括一系列会议,其中介绍和讨论了正在开发的化合物。本进展报告总结了临床前和,当可用时,临床前或早期临床开发中五种不同研究化合物的1期临床数据,即GAO-3-02,GRT-X,NBI-921352(原XEN901),OV329和XEN496(瑞替加滨/埃扎他滨的儿科颗粒制剂)。总的来说,本报告中提供的数据说明了开发抗癫痫药物的新策略,包括对新型分子靶标的兴趣,以及寻求针对罕见和以前被忽视的严重癫痫综合征的潜在新疗法的趋势。
The Eilat Conferences have provided a forum for discussion of novel treatments of epilepsy among basic and clinical scientists, clinicians, and representatives from regulatory agencies as well as from the pharmaceutical industry for 3 decades. Initially with a focus on pharmacological treatments, the Eilat Conferences now also include sessions dedicated to devices for treatment and monitoring. The Sixteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVI) was held in Madrid, Spain, on May 22-25, 2022 and was attended by 157 delegates from 26 countries. As in previous Eilat Conferences, the core of EILAT XVI consisted of a sequence of sessions where compounds under development were presented and discussed. This progress report summarizes preclinical and, when available, phase 1 clinical data on five different investigational compounds in preclinical or early clinical development, namely GAO-3-02, GRT-X, NBI-921352 (formerly XEN901), OV329, and XEN496 (a pediatric granular formulation of retigabine/ezogabine). Overall, the data presented in this report illustrate novel strategies for developing antiseizure medications, including an interest in novel molecular targets, and a trend to pursue potential new treatments for rare and previously neglected severe epilepsy syndromes.